Document is current
Any future updates will be listed below
-
Authors
Nijhuis, Frouke A. P. https://orcid.org/0000-0003-1751-8650
Schippers, Bas
Bloem, Bastiaan R.
Post, Bart
Meinders, Marjan J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
ntr6649 at Netherlands National Trial RegisterDocuments that mention this clinical trial
A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson’s disease: results of a mixed methods feasibility study
https://doi.org/10.1007/s00415-025-12972-x
- License Information
-
More Information
Article History
Received: 3 July 2024
Revised: 12 December 2024
Accepted: 14 February 2025
First Online: 13 March 2025
Declarations
:
: Prof. Bastiaan R. Bloem, MD, PhD, FRCPE, FEAN: Prof. Bloem serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for the Critical Path Institute, Gyenno Science, MedRhythms, UCB, Kyowa Kirin and Zambon (paid to the Institute), has received fees for speaking at conferences from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB and Zambon (paid to the Institute), and has received research support from Biogen, Cure Parkinson’s, Davis Phinney Foundation, Edmond J. Safra Foundation, Fred Foundation, Gatsby Foundation, Hersenstichting Nederland, Horizon 2020, IRLAB Therapeutics, Maag Lever Darm Stichting, Michael J Fox Foundation, Ministry of Agriculture, Ministry of Economic Affairs & Climate Policy, Ministry of Health, Welfare and Sport, Netherlands Organization for Scientific Research (ZonMw), Not Impossible, Parkinson Vereniging, Parkinson’s Foundation, Parkinson’s UK, Stichting Alkemade-Keuls, Stichting Parkinson NL, Stichting Woelse Waard, Topsector Life Sciences and Health, UCB, Verily Life Sciences, Roche and Zambon. Prof. Bloem does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of his clinical or research activities. Grants/research support (paid to the Institute) · Biogen · Cure Parkinson’s · Davis Phinney Foundation · Edmond J. Safra Foundation · Fred Foundation · Gatsby Foundation · Hersenstichting Nederland · Horizon 2020 · IRLAB Therapeutics · Maag Lever Darm Stichting · Michael J Fox Foundation · Ministry of Agriculture · Ministry of Economic Affairs & Climate Policy · Ministry of Health, Welfare and Sport · Netherlands Organization for Scientific Research (ZonMw) · Not Impossible · Parkinson Vereniging · Parkinson’s Foundation · Parkinson’s UK · Stichting Alkemade-Keuls · Stichting Parkinson NL · Stichting Woelse Waard · Topsector Life Sciences and Health · UCB · Verily Life Sciences · Roche · Zambon. Consultant (paid to the Institute) · Critical Path Institute · Gyenno Science · UCB · Zambon SPEAKING (paid to the Institute) · AbbVie · Bial · Biogen · GE Healthcare · Oruen · Roche · UCB · Zambon STOCK SHAREHOLDER None. Memberships · Officer of the Movement Disorder Society (currently Secretary) · Member Executive Scientific Advisory Board (ESAB) of the Michael J Fox Foundation for Parkinson Research · Co-Editor in Chief, Journal of Parkinson’s Disease · Member of the Editorial Board, Digital Biomarkers · Member of the editorial board, Practical Neurology · Member Critical Path Institute for Parkinson (). Other financial disclosures None. The other authors have no competing interests to declare that are relevant to the content of this article.
: The study was approved by the Medical Research Ethics Commission CMO Arnhem-Nijmegen in the Netherlands (registration number 2014–1489). All patients gave written informed consent prior to participating in this study and to audio-tape the consultations. The study has been registered in the Dutch Trial register, NTR6649 (available through ICTRP search portal).
